---
source_url: https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/diarrhea
content_type: therapeutic_choices
document_id: diarrhea
source_system: CPS (Canadian Pharmacists Association)
processed_at: '2025-05-29T07:19:40.930612Z'
processing_stage: url_preservation_final
pipeline_version: '1.0'
download_date: unknown
converted_from: diarrhea.html
redownload_instructions:
  method: Use unified downloader
  command: python cps_unified_downloader.py --types therapeutic_choices
  note: Requires valid CPS access credentials
---

# Diarrhea

### Diarrhea

|  |
| --- |
| Dina Kao, MD, FRCPC |
| Date of Revision: December 7, 2023 |
| Peer Review Date: April 19, 2021 |


#### Introduction

Rome IV criteria define diarrhea as loose or watery stools, without predominant abdominal pain or bothersome bloating, occurring in >25% of stools.‚Äã[^[1]] Clinically, stool consistency between types 5‚Äì7 on the Bristol stool form scale may be used to guide diagnosis (see Constipation in Adults for Bristol scale).‚Äã[^[2]] Increased loss of fecal water and electrolytes occurs with the increased excretion of fecal matter. Patients who have other gastrointestinal symptoms, such as fecal incontinence or fecal urgency, or who notice a change in stool consistency, may refer to it as diarrhea. These symptoms will need to be ruled out before a true diagnosis of diarrhea is given.

Diarrhea may be defined as acute (<14 days in duration), persistent (14‚Äì30 days in duration) or chronic (>30 days in duration).‚Äã[^[3]] While acute diarrhea is often caused by infection (see Table 1), the causes of chronic diarrhea are not always clear. As diagnostic tests are often not readily available, a specific diagnosis may not be possible. Patients who present with chronic diarrhea pose a diagnostic and therapeutic challenge to clinicians.‚Äã[^[5]] During the initial evaluation of these patients, it may be useful to categorize the various etiologies of chronic diarrhea by typical stool characteristics (see Table 2).

#### Goals of Therapy



#### Investigations

Key questions prior to treatment:‚Äã[^[3]]‚Äã[^[6]]‚Äã[^[7]]



#### Acute Diarrhea

#### Etiology

Identifying the etiology of acute diarrhea as presented in Table 1 is critical to therapy.

| Acute Diarrhea |
| --- |
| InfectionsBacteria: e.g., Escherichia coli, Salmonella spp., Shigella spp., Campylobacter spp., Clostridioides difficileParasites or Protozoa: e.g., Cryptosporidium, Cyclospora, Entamoeba histolytica, Giardia lamblia, MicrosporidiaViruses: e.g., adenovirus, norovirus, rotavirus |
| Food allergies |
| Food poisoning: e.g., Staphylococcus aureus toxin |
| Medications: e.g., antibiotics, colchicine, magnesium supplements, metformin, NSAIDs, PPIs |
| Initial presentation of chronic diarrhea |


Reprinted with permission of Elsevier. Schiller L, Sellin J. Diarrhea. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology/diagnosis/management. 10th ed. Philadelphia (PA): Elsevier; 2016. See www.elsevier.com.

#### Infectious Diarrhea



#### Antibiotic-Associated Diarrhea



#### Chronic Diarrhea

Figure 2 illustrates the evaluation of chronic diarrhea; Table 2 outlines the conditions to consider in the differential diagnosis of chronic diarrhea.

Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are 2 conditions commonly associated with chronic diarrhea. The Rome IV diagnostic criteria for IBS are recurrent abdominal pain on average at least 1 day per week in the past 3 months associated with 2 or more of the following: a change in frequency of stool, a change in appearance of stool or pain related to defecation. Symptom onset should be at least 6 months before diagnosis and symptoms should be present during the past 3 months.‚Äã[^[1]] See Irritable Bowel Syndrome. IBD is an idiopathic condition characterized by chronic or relapsing immune activation and inflammation within the gastrointestinal tract. The 2 major forms of IBD are ulcerative colitis (UC) and Crohn disease (CD). UC is restricted to the colon while CD may involve any part of the GI tract. See Inflammatory Bowel Disease.

| Fatty Diarrhea | Inflammatory Diarrhea | Watery Diarrhea |
| --- | --- | --- |
| Malabsorption syndromesMucosal disease, e.g., celiac disease, Whipple diseaseShort gut syndromeSmall intestinal bacterial overgrowthMaldigestionInadequate luminal bile acid concentrationPancreatic exocrine insufficiency | DiverticulitisInfectious diseasesInflammatory bowel diseaseUlcerative colitisCrohn diseaseIschemic colitisNeoplasiaColon cancerLymphomaRadiation colitis | Osmotic diarrheaCarbohydrate malabsorptionOsmotic laxativesSecretory diarrheaBacterial toxinDisordered motility, regulationdiabetic autonomic neuropathyirritable bowel syndromeDiverticulitisEndocrinopathiesCarcinoid syndromeGastrinomaVIPomaPheochromocytomaSomatostatinomaHyperthyroidismAddison disease | Ileal bile acid malabsorptionInflammatory bowel diseaseMedications and toxinsAcid-reducing agents, e.g., H2RAs, PPIsAntibioticsAnti-hypertensives, e.g., beta-adrenergic receptor-blocking drugsLaxative abuseNeoplasiaColon cancerLymphomaVasculitis |


Reprinted with permission of Elsevier. Schiller L, Sellin J. Diarrhea. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology/diagnosis/management. 10th ed. Philadelphia (PA): Elsevier; 2016. See www.elsevier.com.

#### Therapeutic Choices

#### Nonpharmacologic Choices



#### Pharmacologic Choices

Table 4 lists the agents used in the management of diarrhea.

#### Acute Diarrhea

#### Infectious Diarrhea

Use **oral rehydration therapy**** (ORT)** to prevent dehydration and electrolyte loss in both acute and chronic diarrhea (see Dehydration in Children). Oral rehydration solutions should have a balanced sodium-to-glucose ratio. Excess glucose (e.g., Jell-O or soft drinks) or excess sodium (e.g., Gatorade or other sports drinks) may aggravate diarrhea as a consequence of their osmotic effect. Early use of ORT is essential for young children and the elderly.

Balanced electrolyte oral rehydration solutions are available commercially without prescription, e.g., Gastrolyte, Pedialyte. If necessary, a similar solution can be made by adding one-half teaspoonful (2.5 mL) of salt and 6 teaspoonfuls (30 mL) of sugar to 4 cups (1 L) of water.‚Äã[^[13]]‚Äã[^[14]]

Aside from travellers‚Äô diarrhea (see Travellers' Diarrhea), empiric **antibiotic** treatment is not generally recommended for acute diarrhea because of the self-limiting nature of most illnesses, the cost of treatment, the potential for promoting antimicrobial resistance and the possibility of adverse drug reactions.‚Äã[^[13]]‚Äã[^[15]]

Bismuth subsalicylate has been shown to be effective in small cohort studies in the treatment of acute diarrhea and diarrhea caused by microscopic colitis (see Table 4).‚Äã[^[3]]‚Äã[^[16]] Although frequently used in acute diarrheas, there is no clear evidence for its efficacy. The salicylate component can cause gastric and duodenal mucosal damage, particularly in patients who are also taking ASA or NSAIDs. At high doses, the calcium carbonate in the tablet formulation can cause hypercalcemia, hypercalciuria and associated metabolic symptoms. Bismuth-related encephalopathy can result from the use of doses 10 times those recommended or after years of use. Black stools due to bismuth may be confused with melena.

Opioids (codeine, diphenoxylate, loperamide) are effective antimotility agents for symptomatic use in both acute and chronic diarrhea (see Table 4). While adverse effects (e.g., sedation) may limit their use in acute diarrhea, patients usually develop tolerance to these effects with chronic use. Antimotility effects are not desired if the diarrhea is caused by microorganisms because gastrointestinal stasis may enhance the infection.‚Äã[^[13]]‚Äã[^[17]] Codeine offers the additional effects of sedation and analgesia. Diphenoxylate and loperamide have fewer CNS side effects than other opioids. Diphenoxylate is combined with atropine to limit its potential for abuse. Loperamide has the lowest incidence of side effects, is available without prescription, and is effective in patients with ileorectal pouch incontinence and radiotherapy- and chemotherapy-induced diarrhea. Combining loperamide with simethicone provides faster and more complete relief of acute diarrhea associated with gas-related abdominal discomfort.‚Äã[^[18]] While CNS effects are not observed at recommended doses, there are reports of loperamide being abused as an opioid substitute, either to self-treat opioid withdrawal symptoms or to achieve a feeling of euphoria. The supratherapeutic doses (50‚Äì300 mg) taken to achieve CNS opioid effects have been associated with cardiac dysrhythmias and death.‚Äã[^[12]]‚Äã[^[19]] Typical symptoms of opioid toxicity may also be present.‚Äã[^[20]] Health-care practitioners should exercise caution when recommending or providing loperamide to patients with a risk of, or history of, opioid abuse.

Probiotics are live microorganisms that confer a health benefit on the host when administered in adequate amounts.‚Äã[^[21]] It should be noted that within species, different strains of microbes can have widely different biological activities. Furthermore, many effects of these microbiota are strain- and dose-specific. Although there have been multiple studies examining probiotics for various conditions, including C. difficile infection, inflammatory bowel disease and irritable bowel syndrome, there are still significant knowledge gaps. It has been difficult to draw conclusions from meta-analyses or systematic reviews because of differences in strains and doses of microbes used, study design (e.g., included populations, follow-up durations, end points and outcomes), and relatively small sample sizes. Currently, there is insufficient evidence to recommend the routine use of probiotics as part of clinical practice.‚Äã[^[21]]

#### Clostridioides difficile Infection

Management of C. difficile‚Äìassociated diarrhea consists of the following key steps: diagnose C. difficile infection (CDI), prevent spread, cease causative antibiotic, implement supportive measures in severe cases (hospitalization, rehydration, correction of electrolyte imbalances) and eradicate CDI. 

Eradication therapy is required in patients with symptoms (usually diarrhea) and confirmed diagnosis of CDI (positive stool test for C. difficile toxin) or visual confirmation of pseudomembranous colitis. Therapy may be initiated prior to confirmed diagnosis in the presence of high clinical suspicion and severe symptoms. There is no evidence to support screening for asymptomatic C. difficile carriers.‚Äã[^[10]]

Table 3 outlines the assessment and management of CDI. Vancomycin and fidaxomicin are the preferred agents for an initial episode of CDI; metronidazole may be considered for nonsevere CDI only.‚Äã[^[10]]‚Äã[^[22]]

A first CDI relapse will occur in approximately 25% of patients and should be managed based upon the choice of first-line therapy used.‚Äã[^[10]] A second relapse should be investigated for other causes of diarrhea and, if C. difficile is confirmed, treated with a tapered or pulsed vancomycin oral regimen; a standard vancomycin regimen followed by rifaximin therapy; or a standard fidaxomicin regimen. For a third or subsequent recurrence, consider referral for fecal microbiota transplantation (FMT).‚Äã[^[10]]

Fecal microbiota transplantation (FMT) is the transfer of donor stool from a healthy individual to a sick patient, either by colonoscopy or oral capsule delivery. It has been shown to restore intestinal dysbiosis and is highly effective in treating recurrent CDI with a success rate of at least 90% after a single treatment.‚Äã[^[23]]‚Äã[^[24]]‚Äã[^[25]]‚Äã[^[26]] There is retrospective evidence suggesting that FMT has mortality benefit in severe CDI, but not in nonsevere cases.‚Äã[^[27]]‚Äã[^[28]] The short-term safety profile has been excellent; however, there have been a few case reports of FMT resulting in infectious transmission, including transmission of multi-drug resistant E. coli and toxin-producing E. coli.‚Äã[^[29]] Such risks can be mitigated by more rigorous donor screening. Although Health Canada considers FMT to be an investigational new biologic drug, there is a policy in place that permits FMT outside of a clinical trial for the treatment of patients with recurrent CDI not responsive to conventional therapies.‚Äã[^[30]] Despite this provision, access to FMT is still limited, partly due to restrictions set by regional health authorities and partly due to a lack of funding. Investigations of products to eliminate potential risks due to changes in donor health are in early stages of investigation.‚Äã[^[31]]

Bezlotoxumab is a therapeutic adjunct for recurrent CDI which is available in the United States but not yet in Canada. It is a human monoclonal antibody against C. difficile toxin B that has proven more effective than placebo in reducing the rates of recurrent CDI following a course of standard anti-CDI therapy.‚Äã[^[32]]

For patients requiring treatment with antimicrobials during or shortly after the completion of their C. difficile therapy, concomitant oral vancomycin can be considered until the antimicrobials are stopped. A retrospective study found vancomycin prophylaxis in this context to be an effective strategy for decreasing the risk of further CDI recurrence in patients re-exposed to antibiotics.‚Äã[^[33]]

There is no role for probiotic monotherapy in the acute treatment or prevention of CDI in adults and children;‚Äã[^[34]] however, the probiotic Saccharomyces boulardii may be marginally effective when used in conjunction with antibiotic treatment to prevent C. difficile recurrence.‚Äã[^[35]]‚Äã[^[36]] There is no evidence that adding cholestyramine, colestipol or rifampin to the antibiotic treatment regimen decreases the risk of further recurrence, and resins are contraindicated with antibiotics since they can bind to and sequester antibiotics in the gut.‚Äã[^[10]]

Antimotility agents should be avoided in symptomatic CDI because their use increases the risk of toxin retention and precipitation of toxic megacolon.‚Äã[^[37]]

| Severity | Treatment |
| --- | --- |
| Non-severe disease | Vancomycin 125 mg QID PO √ó 10 daysorFidaxomicin 200 mg BID PO √ó 10 daysor (if vancomycin or fidaxomicin unavailable)Metronidazole 500 mg TID PO √ó 10 days |
| Severe disease | Vancomycin 125 mg QID PO √ó 10 daysorFidaxomicin 200 mg BID PO √ó 10 days |
| Fulminant disease | Vancomycin 500 mg QID PO+Metronidazole 500 mg Q8H IV+ (if ileus present)Vancomycin 500 mg in 100 mL saline Q6H PR as retention enema |
| First recurrence | If metronidazole used for initial episode: Vancomycin 125 mg QID PO √ó 10 daysIf vancomycin used for initial episode:Fidaxomicin 200 mg BID PO √ó 10 daysIf vancomycin standard regimen used for initial episode: Vancomycin tapered and pulsed regimen:Vancomycin 125 mg QID PO √ó 10‚Äì14 daysVancomycin 125 mg BID PO √ó 7 daysVancomycin 125 mg once daily PO √ó 7 daysVancomycin 125 mg Q2‚Äì3 days PO √ó 2‚Äì8 wk |
| Second recurrence | Vancomycin tapered and pulsed regimenVancomycin 125 mg QID PO √ó 10 days; followed by rifaximin 400 mg TID PO √ó 20 daysorFidaxomicin 200 mg BID PO √ó 10 days |
| Third or subsequent recurrence | As per second recurrenceorFecal microbiota transplantation |


#### Chronic Diarrhea

See Infectious Diarrhea for a discussion of ORT and opioids.

#### Hydrophilic Bulking Agents

Although psyllium may reduce nonspecific diarrheal symptoms, its role in the management of diarrhea is limited. Many psyllium-containing products are combined with laxatives; avoid these products in patients with diarrhea.

Cholestyramine resin is useful in treating bile acid‚Äìinduced diarrhea due to malabsorption of bile acids in diseased ileum (e.g., Crohn disease) or in some cases of irritable bowel syndrome where rapid transit results in loss of bile acids into the colon.

#### Alpha2-adrenergic Agonists

Clonidine may be effective for diarrhea in irritable bowel syndrome, opioid withdrawal and diabetic autonomic neuropathy.‚Äã[^[38]] The dose required to achieve an antidiarrheal effect may be associated with sedation, dry mouth and orthostatic hypotension.

#### Somatostatin Analogues

Somatostatin analogues can be administered subcutaneously daily (octreotide) or intramuscularly monthly (**octreotide acetate**, lanreotide **acetate**). These agents have been used to control diarrhea caused by neuroendocrine tumors (VIPoma, carcinoid, medullary carcinoma of the thyroid). Octreotide also limits idiopathic and infant secretory diarrhea, as well as diarrhea associated with ileostomy, short bowel syndrome, diabetic neuropathy, chemotherapy, bone marrow transplant, cryptosporidia, graft versus host disease and HIV infection.

Somatostatin has a short half-life and requires continuous IV infusion, which limits its role in the management of diarrhea.

#### Public Health Considerations



#### Choices during Pregnancy and Breastfeeding

Bulk-forming agents, e.g., psyllium, are first choice in treating diarrhea in pregnancy.‚Äã[^[39]] Having limited human pregnancy data, loperamide is considered second line for treatment of diarrhea in pregnancy.‚Äã[^[39]] A prospective clinical trial of 89 patients exposed to loperamide in the first trimester of pregnancy found no increased risk of major malformations compared with matched controls.‚Äã[^[40]] A retrospective analysis of 651 patients exposed to loperamide in early pregnancy found a slightly increased risk of malformation, although many treatment parameters were unknown and multitesting impacted results.‚Äã[^[41]]‚Äã[^[42]] Diphenoxylate/‚Äãatropine should not be used during pregnancy or breastfeeding since it has been found to be teratogenic in animals‚Äã[^[43]] and its active metabolite is probably excreted in breast milk.‚Äã[^[43]]

Cholestyramine is used to treat cholestasis of pregnancy and can be used to manage diarrhea resulting from ileal resection or cholecystectomy.‚Äã[^[44]] Use it with caution during pregnancy or breastfeeding since fat-soluble vitamin deficiency and coagulopathy can occur. Avoid bismuth subsalicylate in pregnancy because salicylates can be absorbed and may lead to increased perinatal mortality, premature closure of the ductus arteriosus, neonatal hemorrhage, decreased birth weight, prolonged gestation and labour, and possible teratogenicity.‚Äã[^[45]] Salicylates should be used cautiously while breastfeeding since they are transferred into breast milk.

Metronidazole is not associated with congenital malformations.‚Äã[^[46]]‚Äã[^[47]]‚Äã[^[48]] It is transferred into breast milk, and breastfeeding should be suspended until treatment with this drug is completed.‚Äã[^[49]] Vancomycin has not been shown to have adverse effects in pregnant patients. There is limited human data on its use while breastfeeding, but it is probably safe.

A discussion of general principles on the use of medications in these special populations can be found in Drugs Use during Pregnancy and Drug Use during Breastfeeding. Other specialized reference sources are also provided in these appendices.

#### Therapeutic Tips



#### Algorithms

![](images/diarrhea_evaacudia.gif)


**AI Image Description:**
The image is a flowchart for managing a patient experiencing diarrhea. Here's a detailed description of its contents:

1. **Initial Assessment:**
   - **Start:** Patient is experiencing diarrhea.
   - **Decision Point:** Are there any red flags? (Refer to Table 1)

2. **If Red Flags are Present:**
   - **Action:** Oral rehydration therapy and further assessment are required.
   - **Clinical Assessment:** 
     - **Assess:**
       - Duration
       - Epidemiologic setting
       - Host immunocompetence
       - Severity of illness
   - **Clinically Important Diarrhea:**
     - Criteria:
       - Duration > 3 days
       - Fecal white blood cells or bloody diarrhea
       - Impaired host defense
       - Volume depletion
     - **If Yes:** Rehydration and diagnostic workup as directed by clinical information.
     - **If No:** Rehydration, symptomatic therapy.
     - **Outcome:** 
       - If diarrhea continues, refer to treatment with antidiarrheal agents (see Table 8).
       - If diarrhea resolves, no further action.

3. **If No Red Flags are Present:**
   - **Action:** Oral rehydration therapy with options:
     - Loperamide (for moderate-severe diarrhea)
     - Bismuth subsalicylate (for mild-moderate diarrhea)
     - Psyllium (for mild diarrhea)
   - **Decision Point:** Does diarrhea improve within 48 hours?
     - **If Yes:** Continue oral rehydration therapy until diarrhea stops. Consider stopping antidiarrheal medication when diarrhea resolves.
     - **If No:** Try loperamide for 24 hours (if not tried already).
     - **Further Decision Point:** Does diarrhea resolve?
       - **If Yes:** No further action.
       - **If No:** Continue assessment and treatment as needed.

This flowchart provides a structured approach to assessing and managing diarrhea, emphasizing rehydration and appropriate use of medications based on severity and duration.

*AI-generated description for accessibility and content understanding*


![](images/diarrhea_evachrdia.gif)


**AI Image Description:**
The image is a flowchart for diagnosing and managing chronic diarrhea. Here's a detailed description of its contents:

1. **Chronic Diarrhea**:
   - Initial step involves excluding:
     - Iatrogenic problems: medications, surgery
     - Infections: *Giardia*, *C. difficile*
     - Other medical conditions: thyroid dysfunction, celiac disease

2. **Pathways**:
   - **Inflammatory Diarrhea**:
     - Action: Colonoscopy + biopsy

   - **Fatty Diarrhea**:
     - Action: Small bowel imaging, biopsy; consider pancreatic imaging if clinical suspicion is present

   - **Pain Aggravated Before BM, Relieved with BM, Sense of Incomplete Evacuation**:
     - Suspect IBS (Irritable Bowel Syndrome)

   - **No Worrisome Features**:
     - Consider functional diarrhea
     - Dietary exclusion (e.g., lactose, sorbitol)

3. **Limited Screen for Organic Disease**:
   - Tests: Hematology, chemistry, CRP, Fe, folate, Vit B‚ÇÅ‚ÇÇ, anti TTG, stool for fat (qualitative)

4. **Outcomes Based on Screening**:
   - **Low Hb, MCV, Albumin, Vit B‚ÇÅ‚ÇÇ; Excess Stool Fat**:
     - Colonoscopy + biopsy
     - Small bowel imaging, biopsy; consider stool 48-hour fat test

   - **Low Serum K‚Å∫**:
     - Stool osmolarity, pH; laxative screen; hormonal screen (e.g., gastrin, VIP)

   - **Normal Screening Tests**:
     - Empiric therapy (e.g., opioid, bile acid sequestrant)

This flowchart provides a structured approach to diagnosing and managing chronic diarrhea, considering various potential causes and appropriate diagnostic tests.

*AI-generated description for accessibility and content understanding*


bowel movement

C-reactive protein

erythrocyte sedimentation rate

hemoglobin

irritable bowel syndrome

mean corpuscular volume

tissue transglutaminase

vasoactive intestinal peptide

Reprinted from Camilleri M, Sellin JH, Barrett KE. Pathophysiology, evaluation, and management of chronic watery diarrhea. *Gastroenterology* 2017;152(3):515-32; with permission from Elsevier.

#### Drug Table


**Drug Class: Alpha2-adrenergic Agonists**


**Drug Class: Antibacterial Agents**


**Drug Class: Hydrophilic Bulking Agents**


**Drug Class: Intestinal Adsorbants**


**Drug Class: Opioids**


**Drug Class: Resins**


**Drug Class: Somatostatin Analogues**

| Drug/‚ÄãCost[a] | Dosage | Adverse Effects | Drug Interactions | Comments |
| --- | --- | --- | --- | --- |
| **clonidine** (generics) | 0.1‚Äì0.3 mg BID PO‚Äã[38]may titrate to effectnot to exceed 1.2 mg/day | Centrally mediated sedation and hypotension. | Additive effects with drugs that cause hypotension. |  |
| **fidaxomicin** (Dificid) | 200 mg BID PO √ó 10 days | Constipation, nausea, rash, vomiting. | No significant drug interactions. | Expensive. May be considered in patients experiencing more than 2 occurrences of C. difficile‚Äìassociated diarrhea. |
| **metronidazole** (Flagyl, generics) | Non-severe Clostridioides difficile diarrhea: 500 mg TID PO √ó 10 days (if vancomycin or fidaxomicin unavailable)Fulminant C. difficile diarrhea: 500 mg Q8H IV (in combination with vancomycin) | Nausea, headache, anorexia, dry mouth, metallic taste in mouth. | Metronidazole may potentiate warfarin; monitor INR when metronidazole is added or discontinued and adjust warfarin dose accordingly.Disulfiram-like reaction with alcohol: avoid alcohol intake during treatment and for 48 h after treatment. | Refrain from using for third or subsequent occurrences to avoid drug accumulation and neurotoxicity. |
| **vancomycin** (Vancocin, generics) | Non-severe or severe C. difficile diarrhea: 125 mg QID PO √ó 10 daysFulminant C. difficile diarrhea: 500 mg QID PO (in combination with metronidazole; if ileus present, add vancomycin retention enema)Tapered and pulsed regimen for recurrence of C. difficile diarrhea (see Table 3): 125 mg QID PO √ó 10‚Äì14 days 125 mg BID PO √ó 7 days 125 mg daily PO √ó 7 days125 mg PO Q2‚Äì3 days √ó 2‚Äì8 wk | Bitter taste, nausea, vomiting, stomatitis, chills, drug fever, eosinophilia. | Minimal with oral administration. | Poorly absorbed after oral administration. |
| **psyllium hydrophilic mucilloid** (Metamucil, generics) | 1 teaspoon (5‚Äì6 g) Q12H PO | Inhalation of psyllium powder may cause allergic reactions. |  | Treats diarrhea by absorbing liquid to create firmer stool, which is slower to pass.Take with fluids.Avoid combinations with laxatives. |
| **bismuth subsalicylate** (Pepto-Bismol, generics) | 30 mL (17.6 mg BSS/mL) Q30 min PO to a maximum of 8 doses/day | Salicylate toxicity, black tongue, black stool, bismuth-induced encephalopathy. | Decreases absorption of fluoroquinolones, doxycycline and tetracycline. | Caution with use in renal insufficiency. |
| **bismuth subsalicylate with calcium carbonate** (Pepto-Bismol) | 2 tablets (262 mg BSS/tablet) Q30 min PO to a maximum of 8 doses/day | Salicylate toxicity, black tongue, black stool, bismuth-induced encephalopathy.Hypercalcemia, hypercalciuria. | Decreases absorption of fluoroquinolones, doxycycline and tetracycline. | Caution with use in renal insufficiency. |
| **codeine** (generics) | 30‚Äì60 mg Q4H PRN PO | Sedation, nausea, tolerance; potentially addictive. | Additive CNS depression with CNS depressants. | Elderly may be particularly susceptible to the adverse effects. |
| **diphenoxylate** (Lomotil) | 5 mg PO initially then 2.5 mg PO after each loose bowel movement (maximum of 20 mg/day) | Sedation, nausea, abdominal cramps, dry skin and mucous membranes (from atropine); some addiction potential. | Additive anticholinergic effects with other anticholinergic agents. | Elderly are more susceptible to the anticholinergic effects of atropine, e.g., agitation, drowsiness, increased intraocular pressure. |
| **loperamide** (Imodium, generics) | 2 mg PO after each loose bowel movement (maximum of 16 mg/day) | Sedation, nausea, abdominal cramps.Lowest addiction potential of all opioids. |  | Reports of loperamide being abused as an opioid substitute; higher than recommended doses can lead to cardiac dysrhythmia and death.‚Äã[12] |
| **cholestyramine resin** (Cholestyramine-Odan, other generics) | 4 g Q12H PO | Nausea, fat-soluble vitamin deficiency with long-term use, constipation. | May bind drugs, e.g., digoxin, in GI tract; administer other medications at least 1 h before or 4‚Äì6 h after cholestyramine. | Take with fluids. |
| **lanreotide acetate** (Somatuline autogel) | 60 mg monthly IM | Pain at injection site, nausea, mild diarrhea. | Hypoglycemia or hyperglycemia can occur as a result of inhibition of insulin and glucagon secretion. Monitor blood glucose concentrations when lanreotide therapy is initiated or dosage adjusted in patients with diabetes mellitus. Adjust dose of antidiabetic agents as necessary. |  |
| **octreotide acetate** (Sandostatin, generics) | 50‚Äì500 mcg Q12H SC | Pain at injection site, nausea, mild diarrhea. | Hypoglycemia or hyperglycemia can occur as a result of altered balance between the counter-regulatory hormones, e.g., insulin, glucagon, growth hormone. Adjustment of the dosage of drugs affecting glucose metabolism may be required following initiation of therapy. | Monitor glucose tolerance and antidiabetic treatment periodically. |
| **octreotide acetate, long-acting** (Sandostatin, generics) | 10‚Äì30 mg monthly IM | Pain at injection site, nausea, mild diarrhea. | Hypoglycemia or hyperglycemia can occur as a result of altered balance between the counter-regulatory hormones, e.g., insulin, glucagon, growth hormone. Adjustment of the dosage of drugs affecting glucose metabolism may be required following initiation of therapy. | Monitor glucose tolerance and antidiabetic treatment periodically. |


**ü´ò Renal Monitoring - Monitor kidney function when using this medication**

<!-- AI description pending for: images/kidney.gif -->

bismuth subsalicylate

central nervous system

gastrointestinal

international normalized ratio

long-acting release

#### Suggested Readings

Arasaradnam RP, Brown S, Forbes A et al. Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. *Gut* 2018;67(8):1380-99.

Lucak S, Chang L, Halpert A et al. Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. *Therap Adv Gastroenterol* 2017;10(2):253-75.

McDonald LC, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis* 2018;66(7):e1-e48.

Quraishi MN, Widlak M, Bhala N et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. *Aliment Pharmacol Ther* 2017;46(5):479-93.

Smalley W, Falck-Ytter C, Carrasco-Labra A et al. AGA clinical practice guidelines on the laboratory evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults (IBS-D). *Gastroenterology* 2019;157(3):851-4.

#### References


---

## Source Information

**Original Source:** [https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/diarrhea](https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/diarrhea)  
**Content Type:** therapeutic_choices  
**Processed:** 2025-05-29 07:19 UTC  
**Source System:** Canadian Pharmacists Association (CPS)

### How to Cite
> Canadian Pharmacists Association. *diarrhea*. 
> CPS Online. Retrieved 2025-05-29 07:19 UTC from https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/diarrhea


```

*Note: This document was processed using automated tools. Always refer to the original source for the most up-to-date information.*

---
*Document processed with CPS Pipeline v1.0 ‚Ä¢ [Source URL](https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/diarrhea)*
